Navigation Links
Phase II study shows HRPC patients with bone metastases see improved survival with ZD4054
Date:9/25/2007

d be an important treatment option for patients with HRPC. In addition, ZD4054 has a manageable side-effect profile, which included headache, oedema and nasal congestion.1

The Phase II EPOC study design: This study recruited a total of 312 asymptomatic or mildly symptomatic HRPC patients with bone metastases who were randomised into one of three treatment arms: 15mg ZD4054 once-daily; 10mg ZD4054 once daily or a placebo tablet once-daily. In addition to study treatment, all men randomised into the study received best supportive care.

Mode of action specific ETA receptor antagonism:

ZD4054 works by specifically blocking the ETA receptor. This may lead to the inhibition of multiple processes that drive tumour growth and spread, including tumour cell proliferation, tumour cell survival, angiogenesis and the formation of bone metastases.2 It does so without blocking the ETB receptor, which may provide beneficial biological effects in terms of encouraging apoptosis, the death of unhealthy cells.

The future of ZD4054:

ZD4054 has shown promising results in this Phase II study in patients with metastatic hormone resistant prostate cancer, said Alex Oldham, ZD4054 Vice President. AstraZeneca is committed to confirming these findings and further evaluating the activity of ZD4054 in HRPC through a comprehensive Phase III clinical development programme.

The three Phase III trials will investigate a 10mg once-daily dose of ZD4054.

AstraZeneca has a well-established prostate cancer franchise based on its leading hormonal treatments ZOLADEX (goserelin), first launched in 1987, and CASODEX (bicalutamide), first launched in 1995.


'/>"/>

Contact: Aoife Gallagher
aoife_gallagher@uk.cohnwolfe.com
44-078-943-86422
Cohn & Wolfe Healthcare, London
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. FDA approves Phase 0 trial which tests experimental drugs on humans
2. SARS-Free Taiwan to Mark End Phase of Global Fight
3. S. Africa AIDS in death phase
4. Spray on contraceptive clears Phase I trial
5. Phase 3 trials of two multi-kinase inhibitors against cancer
6. Antigenics Pharmaceuticals plans for Phase III trial of its Melanoma vaccine
7. Phase II trails of new HIV vaccine to be held in South Africa
8. Phase 1 Drug Trials on Humans to Be Made Public
9. Jalgaon: Third Phase Of Culling Operations Begin
10. Lupin Gets DCGI Nod For Phase II Clinical Trials On Desoside-P
11. Cadila to Commence Phase I Clinical Trials On ZYH2
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... UK (PRWEB) , ... September 01, 2015 , ... ... a vacuum that creates negative pressure inside a wound to remove exudates, fluid, ... for treatment devices (comprising portable devices, stand-alone devices, disposable devices, and canisters, etc.) ...
(Date:9/1/2015)... (PRWEB) , ... September 01, 2015 , ... ... it is now offering the MonaLisa Touch® , an innovative vaginal health ... MonaLisa Touch® is a new hormone-free treatment for atrophic vaginitis, a condition that ...
(Date:9/1/2015)... , ... September 01, 2015 ... ... Background Screeners (NAPBS®) has announced that Edge Information Management has been ... the Background Screening Credentialing Council (BSCC). , ÔÇťAchieving and maintaining this ...
(Date:9/1/2015)... ... 2015 , ... PetPace, the provider of an innovative IoT ... today announced its integration with leading veterinary Practice Management Software vendor Cornerstone. ... Management Software packages in the US. Practice Management Software helps veterinarians manage every ...
(Date:9/1/2015)... ... September 01, 2015 , ... Discovia, ... entities, announced today that it has hired Scott Sanderson, an experienced business development ... capacity, Sanderson will be responsible for establishing and managing new client relationships in ...
Breaking Medicine News(10 mins):Health News:World Negative Pressure Wound Therapy Market Assessed by GlobalData in In-demand Report Published at MarketPublishers.com 2Health News:World Negative Pressure Wound Therapy Market Assessed by GlobalData in In-demand Report Published at MarketPublishers.com 3Health News:Houston's Plaza OB/GYN Now Offering the MonaLisa Touch® 2Health News:Houston's Plaza OB/GYN Now Offering the MonaLisa Touch® 3Health News:Edge Information Management Granted Continued NAPBS Accreditation 2Health News:Edge Information Management Granted Continued NAPBS Accreditation 3Health News:Petpace-Cornerstone Integration Lowers Overhead, Raises Data Visibility for Veterinary Practices 2Health News:Former NFL Standout Scott Sanderson Joins eDiscovery Leader Discovia 2
... interventions in future, study finds , , TUESDAY, April 7 ... two years after a diagnosis of early bladder cancer ... finds. , Researchers analyzed data on 20,713 Medicare patients ... The average cost of care for patients who received ...
... and possession of alcohol, zero tolerance prevent more than ... 7 (HealthDay News) -- Not all laws are created ... drinking-related auto accidents, say researchers who analyzed the impact ... Most effective, they found, are laws targeting the purchase ...
... scans improves access for patients to needed cancer ... GE Healthcare, a global leader in healthcare technology, ... the Centers for Medicare and Medicaid Services (CMS), ... tomography (PET) for Medicare beneficiaries who are diagnosed ...
... research exploring weight discrimination against women in the workplace. , ... , , , ... , , , ... , , , , ...
... offers helpATLANTA, April 7 Struggling with infertility issues ... a reality for some today. The troubled economy has ... shut down. And both women and men have biological ... have a baby but know they need some physical ...
... of a long-secret report by International Committee of the Red Cross ... secret detention centers committed gross violations of medical ethics and in ... ... (Vocus) April 7, 2009 -- The full disclosure of a ...
Cached Medicine News:Health News:Intensive Early Treatment Doesn't Help Bladder Cancer Survival 2Health News:Tough Legislation on Underage Drinking Seems to Save Lives 2Health News:Tough Legislation on Underage Drinking Seems to Save Lives 3Health News:GE Healthcare Applauds CMS for Supporting National FDG-PET Coverage Decision 2Health News:Weight discrimination could contribute to the glass ceiling effect for women, study finds 2Health News:Weight discrimination could contribute to the glass ceiling effect for women, study finds 3Health News:Weight discrimination could contribute to the glass ceiling effect for women, study finds 4Health News:Infertility Issues and No Insurance Do Not Necessarily Mean No Hope for Baby 2Health News:In Wake of ICRC Report, Health Professionals Must Be Held Accountable for Torture 2Health News:In Wake of ICRC Report, Health Professionals Must Be Held Accountable for Torture 3
(Date:9/1/2015)... 2015 Taiwan,s GNT ... in Taipei on  August 25 ... platform, a targeted drug delivery technology that uses nano-scale ... was part of a joint press conference held by ... (GNT), showcasing GNT,s latest edible gold-based food and beverage ...
(Date:9/1/2015)... 1, 2015 Sargas Pharmaceutical Adherence and ... Drug Adherence m Health applications along with 24 ... of non face-to-face monitoring of twenty minutes per ... of our apps, doctors are now well prepared ... our ONCHIT certified Physician, Pharmacy and Patient portals ...
(Date:9/1/2015)... Agena Bioscience TM today announced the establishment ... commercial and financial hub from which many biotech and life ... in mainland China . "The ... sales with almost sixty MassARRAY ® Systems installed to ... allow us to expand our reach and foster a high ...
Breaking Medicine Technology:GNTbm Updates Developments in the Vaucarrin(TM) annogold Drug Delivery Platform 2GNTbm Updates Developments in the Vaucarrin(TM) annogold Drug Delivery Platform 3GNTbm Updates Developments in the Vaucarrin(TM) annogold Drug Delivery Platform 4GNTbm Updates Developments in the Vaucarrin(TM) annogold Drug Delivery Platform 5SPAC International's Drug Adherence and Chronic Care Management App Now available at Apple App and Google Play stores 2Agena Bioscience Opens Office in Shanghai, China 2
... today announced positive results from a Phase 1 trial ... in vitro anti-pseudomonal activity. The results from ... well tolerated, with a clinical and laboratory safety profile ... toxicity was observed, even at the highest dose regimen ...
... 23 Each year in the United States more than ... These new cases account for 10 percent of the new ... several types of leukemia, the survival rate has not changed ... Golubieski, president of Foundation Venture Capital Group, LLC, a New ...
Cached Medicine Technology:Calixa Therapeutics Announces Positive Phase 1 Results for CXA-101, a Novel Intravenous Cephalosporin Antibiotic with Excellent Anti-Pseudomonal Activity 2Foundation Venture Capital Group Invests in UMDNJ Company Working to Improve Leukemia Treatments 2
...
No. 1. 30 mm conventional blades. Thin well-rounded tips....
Open blade speculum designed for both temporal and superior approach ocular surgery. Thumb screw adjusting mechanism. Manufactured in titanium....
Adjustable lid speculum angled 45 degrees with 17 mm curved solid blades and aspiration ports to remove excess fluid from around the eye during ocular procedures....
Medicine Products: